Stocks Health care VERA
NASDAQ · Health careVera Therapeutics, Inc. (VERA)
It posted a net loss of $401.9M. In fiscal 2025 capital spending exceeded operating cash flow by $241.7M. At June 30, 2026 it held $48.9M in cash against $75.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
What Vera Therapeutics, Inc. does
Vera Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VERA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$299.6M | -$4.66 | -$241.7M |
| 2024 | n/a | -$152.1M | -$2.75 | -$135.7M |
| 2023 | n/a | -$96M | -$2.25 | -$92.2M |
| 2022 | n/a | -$89.1M | -$3.35 | -$67.7M |
| 2021 | n/a | -$32.6M | -$2.43 | -$23.7M |
| 2021 | n/a | -$53.4M | -$166.93 | -$34.9M |
Latest SEC filings
What Vera Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 15, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026
- August 10, 2026
- July 30, 2026Passive stake changed SCHEDULE 13G/A
- July 9, 2026
- July 7, 2026Other event 8-K
- June 2, 2026Other event 8-K
- May 26, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Questions about VERA
What does Vera Therapeutics, Inc. do?
Vera Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VERA.
Is Vera Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $401.9M.
When did Vera Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 17, 2026.
Similar companies
Follow VERA
Get an email when Vera Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow VERA: get an email when it filesWhere the numbers come from
Financial figures are the values Vera Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.